Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma von Tam, Constantine S, Anderson, Mary Ann, Pott, Christiane, Agarwal, Rishu, Handunnetti, Sasanka, Hicks, Rodney J, Burbury, Kate, Turner, Gillian, Di Iulio, Juliana, Bressel, Mathias, Westerman, David, Lade, Stephen, Dreyling, Martin, Dawson, Sarah-Jane, Dawson, Mark A, Seymour, John F, Roberts, Andrew W

Volltext

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL von Blombery, Piers, Lew, Thomas E., Dengler, Michael A., Thompson, Ella R., Lin, Victor S., Chen, Xiangting, Nguyen, Tamia, Panigrahi, Ashish, Handunnetti, Sasanka M., Carney, Dennis A., Westerman, David A., Tam, Constantine S., Adams, Jerry M., Wei, Andrew H., Huang, David C.S., Seymour, John F., Roberts, Andrew W., Anderson, Mary Ann

Volltext

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax von Lin, Victor S., Lew, Thomas E., Handunnetti, Sasanka M., Blombery, Piers, Nguyen, Tamia, Westerman, David A., Kuss, Bryone J., Tam, Constantine S., Roberts, Andrew W., Seymour, John F., Anderson, Mary Ann

Volltext

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance von Blombery, Piers, Thompson, Ella R., Lew, Thomas E., Tiong, Ing Soo, Bennett, Rory, Cheah, Chan Y., Lewis, Katharine Louise, Handunnetti, Sasanka M., Tang, Chloe Pek Sang, Roberts, Andrew, Seymour, John F., Tam, Constantine S.

Volltext

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma von Flinsenberg, Thijs W. H., Tromedjo, Charnelle C., Hu, Nan, Liu, Ye, Guo, Yin, Thia, Kevin Y. T., Noori, Tahereh, Song, Xiaomin, Aw Yeang, Han X., Tantalo, Daniela G., Handunnetti, Sasanka, Seymour, John F., Roberts, Andrew W., Ritchie, David, Koldej, Rachel, Neeson, Paul J., Wang, Lai, Trapani, Joseph A., Tam, Constantine S., Voskoboinik, Ilia

Volltext

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition von Lew, Thomas E., Lin, Victor S., Cliff, Edward R., Blombery, Piers, Thompson, Ella R., Handunnetti, Sasanka M., Westerman, David A., Kuss, Bryone J., Tam, Constantine S., Huang, David C.S., Seymour, John F., Roberts, Andrew W., Anderson, Mary Ann

Volltext

Treatment approaches for patients with TP53-mutated mantle cell lymphoma von Lew, Thomas E, Minson, Adrian, Dickinson, Michael, Handunnetti, Sasanka M, Blombery, Piers, Khot, Amit, Anderson, Mary Ann, Ritchie, David, Tam, Constantine S, Seymour, John F

Volltext

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans von Dobie, Gasim, Kuriri, Fahd A., Omar, Musab M.A., Alanazi, Fehaid, Gazwani, Ali M., Tang, Chloe P.S., Sze, Daniel Man-yuen, Handunnetti, Sasanka M., Tam, Constantine, Jackson, Denise E.

Volltext

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months von Lew, Thomas E., Anderson, Mary Ann, Lin, Victor S., Handunnetti, Sasanka M., Came, Neil A., Blombery, Piers, Westerman, David A., Wall, Meaghan, Tam, Constantine S., Roberts, Andrew W., Seymour, John F.

Volltext

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre von Tam, Constantine S., Gregory, Gareth P., Ku, Matthew, Fleming, Shaun, Handunnetti, Sasanka M., Lee, Denise, Walker, Patricia, Perkins, Andrew, Lew, Thomas E., Sirdesai, Shreerang, Chua, Chong Chyn, Gilbertson, Michael, Lasica, Masa, Anderson, Mary Ann, Renwick, William, Grigg, Andrew, Patil, Sush, Opat, Stephen, Friebe, Adam, Cooke, Rachel, De Boer, Jasper, Spencer, Andrew, Ritchie, David, Agarwal, Rishu, Blombery, Piers

Volltext

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors von Thompson, Ella R., Nguyen, Tamia, Kankanige, Yamuna, Markham, John F., Anderson, Mary Ann, Handunnetti, Sasanka M., Thijssen, Rachel, Yeh, Paul Sung-Hao, Tam, Constantine S., Seymour, John F., Roberts, Andrew W., Westerman, David A., Blombery, Piers

Volltext

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon von Lew, Thomas E., Bennett, Rory, Lin, Victor S., Whitechurch, Ashley, Handunnetti, Sasanka M., Marlton, Paula, Shen, Yandong, Mulligan, Stephen P., Casan, Joshua, Blombery, Piers, Tam, Constantine S., Roberts, Andrew W., Seymour, John F., Thompson, Philip A., Anderson, Mary A.

Volltext

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy von Davis, Joanne E., Handunnetti, Sasanka M., Ludford-Menting, Mandy, Sharpe, Chia, Blombery, Piers, Anderson, Mary Ann, Roberts, Andrew W., Seymour, John F., Tam, Constantine S., Ritchie, David S., Koldej, Rachel M.

Volltext

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy von Handunnetti, Sasanka, Anderson, Mary Ann, Roberts, Andrew W., Davids, Matthew S., Ma, Shuo, Boyer, Michelle, Arzt, Jennifer, Masud, Abdullah Al, Popovic, Relja, Jacobson, Amanda, Kim, Su Y., Seymour, John F.

Volltext

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies von Teh, Benjamin W., Tam, Constantine S., Handunnetti, Sasanka, Worth, Leon J., Slavin, Monica A.

Volltext

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia von Lew, Thomas, Anderson, Mary Ann, Tam, Constantine S., Handunnetti, Sasanka, Carney, Dennis, Wall, Meaghan, Roberts, Andrew W., Seymour, John F.

Volltext

Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy von Tang, Chloe Pek Sang, La Gerche, Andre, McMullen, Julie, Howden, Erin, Handunnetti, Sasanka M., Goncalves, Isaac, Ooi, Jenny, Tam, Constantine S.

Volltext

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers von Davis, Joanne, Handunnetti, Sasanka M, Sharpe, Chia, Turner, Gillian, Anderson, Mary Ann, Roberts, Andrew W., Seymour, John F., Tam, Constantine S., Ritchie, David, Koldej, Rachel

Volltext

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia von Thompson, Ella R, Nguyen, Tamia, Kankanige, Yamuna, Anderson, Mary Ann, Handunnetti, Sasanka M., Thijssen, Rachel, Yeh, Paul Sung-Hao, Tam, Constantine S., Seymour, John F., Roberts, Andrew W, Westerman, David Alan, Blombery, Piers

Volltext

Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial von Mato, Anthony R., Roeker, Lindsey E., Allan, John N., Pagel, John M., Brander, Danielle M., Hill, Brian T., Cheson, Bruce D., Furman, Richard R., Lamanna, Nicole, Tam, Constantine S., Handunnetti, Sasanka, Jacobs, Ryan, Lansigan, Frederick, Bhavsar, Erica, Barr, Paul M., Shadman, Mazyar, Skarbnik, Alan P., Goy, Andre, Beach, Douglas F., Svoboda, Jakub, Pu, Jeffrey J., Sehgal, Alison R., Zent, Clive S., Tuncer, Hande H., Schuster, Stephen J., Pickens, Peter V., Shah, Nirav N., Rhodes, Joanna, Ujjani, Chaitra S., Nabhan, Chadi

Volltext